Mineralys Therapeutics Earnings Preview
Portfolio Pulse from Benzinga Insights
Mineralys Therapeutics (NASDAQ:MLYS) is scheduled to release its quarterly earnings report on March 21, 2024, with an expected EPS of $-0.82. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat resulting in a 6.74% drop. Shares are currently trading at $13.48, down 13.18% over the last year. Investors are looking for positive guidance for the next quarter.
March 20, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mineralys Therapeutics is expected to report an EPS of $-0.82 for the upcoming quarter. Historical data shows its stock price reacts variably to earnings reports, with a recent 6.74% drop after the last beat. Currently, shares are down 13.18% over the past year.
Given the mixed historical stock price reaction to earnings reports and the current negative year-to-date performance, the short-term impact of the upcoming earnings report on MLYS's stock price is uncertain. However, the importance of the report is high due to the anticipation of future guidance which could influence investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100